Floatz logo

ARA-GUANOSINE

Non-Hodgkin's Lymphoma

Stanford UniversitySmall moleculePhase 1Active
C
39/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
73/ 100

Competitive context

46 Active assets in the Non-Hodgkin's Lymphoma cohort.

Asset / SponsorPhaseRating
Inno-206
National Cancer Institute (NCI)
Phase 4BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
National Cancer Institute (NCI)
Phase 4BBB
Cyclophosphamide
National Cancer Institute (NCI)
Phase 4BBB
PREDNISONE TABLETS
National Cancer Institute (NCI)
Phase 3BBB
PEGFILGRASTIM
University of Washington
Phase 4BB

View all 50 →

Same molecule, other indications

ARA-GUANOSINE is also rated in:

Alzheimer Disease (AD)Dormant
CCC
Indicative ·
52 / 100
View asset →
Correlate Tracer Uptake to TCell Tumor Infiltration & CkIT BenefitDormant
CCC
Indicative ·
52 / 100
View asset →
Non-small Cell Lung CancerDormant
CCC
Indicative ·
50 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →